e-ISSN: Pending
Failed Experiment ReportOpen accessMedical physics. Medical radiology. Nuclear medicine

A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer

Ma Li; Men Yu; Feng Lingling; Kang Jingjing; Sun Xin; Yuan Meng; Jiang Wei; Hui Zhouguang · 2019 · Radiology and Oncology

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

The finding, in one line

However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.

Abstract

The mainstay therapy for locally advanced non-small cell lung cancer is concurrent chemoradiotherapy. Loco-regional recurrence constitutes the predominant failure patterns. Previous studies confirmed the relationship between increased biological equivalent doses and improved overall survival. However, the large randomized phase III study, RTOG 0617, failed to demonstrate the benefit of dose-escalation to 74 Gy compared with 60 Gy by simply increasing fraction numbers.

Abstract by Ma Li; Men Yu; Feng Lingling; Kang Jingjing; Sun Xin; Yuan Meng; Jiang Wei; Hui Zhouguang, Radiology and Oncology (2019) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.2478/raon-2019-0006